Pharmacy Times

AUGUST 19, 2022

Auvelity uses the first new oral mechanism of action for major depressive disorder in more than 60 years.

FDA 132

FDA 132

The Honest Apothecary

AUGUST 19, 2022

It is my conviction that managers really do make all the difference in the world. Great managers get great results and build great teams. Bad managers don’t. But it is also my conviction that managers generally mirror the leadership culture created by those they report to. There is, if you will, a “trickle down” effect in the style and priorities of your management.

105

105

Pharmacy Times

AUGUST 19, 2022

Douglas Hoey, PharmD, MBA, CEO of National Community Pharmacists Association (NCPA), discusses potential causes and solutions for the current staffing issues facing so many community pharmacies.

Community Pharmacies 132

Community Pharmacies 132

The Thyroid Pharmacist

AUGUST 19, 2022

While I have a lot of stories of people who recovered their health through removing reactive foods, adding in healing foods, and taking the appropriate supplements, I personally did not get my Hashimoto’s into remission by following those steps. Sure, I felt much better, and my thyroid antibodies significantly dropped with the help of nutrition, but eventually my health problems began creeping back in.

Health and Personal Care Stores 98

Health and Personal Care Stores Immunization Insurance Packaging 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

AUGUST 19, 2022

Treatment with empagliflozin also found to improve cardiac geometry, myocardial mechano-energetic efficiency, and cardiac function.

123

123

European Pharmaceutical Review

AUGUST 19, 2022

Rising demand for therapeutics, especially in developing markets, is expected to expand the global pharmaceutical contract manufacturing market to $130.2 billion by 2026. The market was valued at approximately $100 billion in 2020. According to market research , factors promoting the 4.6 percent compound annual growth rate (CAGR) of the market include the increasing commercialisation of generics and emerging technologies and small biotechs with limited or no production capabilities driving devel

Packaging 98

Packaging Compounding 98

DiversifyRx

AUGUST 19, 2022

Thank you to everyone who joined us for the Pharmacy Profit Summit 2022! We are still amazed at the lineup of extraordinary speakers at the summit. . Our event did sell out. We know that not everyone who wanted to attend could; even some with tickets got the dreaded positive test and couldn’t make it. In this blog, we will cover some of the highlights of the summit speakers and how you can learn more about them!

Independent Pharmacies 98

Independent Pharmacies Patient Care 98

Pharmacy Times

AUGUST 19, 2022

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, discussed how mRNA vaccines could change the treatment landscape for respiratory illnesses.

Vaccines 122

Vaccines Immunization 122

Board Vitals - Pharmacist

AUGUST 19, 2022

CCRN certification is a special certification granted by the American Association of Critical Care Nurses (AACN). CCRN certification is valuable for nurses, as it allows RNs to care for patients in acute care and/or critical care setting. We’ve compiled some of the most frequently asked questions about CCRN certification to help you prepare for the exam and maintain your licensure.

Hospitals 94

Hospitals 94

Pharmacy Times

AUGUST 19, 2022

Oncology pharmacists must think critically about the digital experience they give patients.

Specialty Pharmacies 101

Specialty Pharmacies 101

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Luxe Pharmacist

AUGUST 19, 2022

Hello friends, I cannot wait for my girlfriends bachelorette this weekend in Miami! (Currently publishing this from the airport). I’m expecting a lot of heat given that it’s mid August, so I figured I may as well bring the heat as well! I’m sharing everything I packed and more if you need some inspiration for an upcoming bachelorette trip, date night, girls night out or tropical vacay.

93

93

Pharmacy Times

AUGUST 19, 2022

Ed Cohen, PharmD, FAPhA, drives a discussion around the new inclusion of infants as young as 6 months old within the COVID-19 vaccine recommendations and how to educate parents on the topic.

Vaccines 94

Vaccines 94

Pharmaceutical Commerce

AUGUST 19, 2022

Optimizing the use of data and improving the patient experience go hand in hand.

69

69

Pharmacy Times

AUGUST 19, 2022

Strategies for pediatric-specific care are explored, with an emphasis on vaccine advocation and administration geared toward parents and caregivers.

Vaccines 94

Vaccines 94

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

AUGUST 19, 2022

NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma

52

52

Pharmacy Times

AUGUST 19, 2022

Broncochem is an expectorant syrup to help cough symptoms.

65

65

Pharma Times

AUGUST 19, 2022

Senior public health figures take unusual step of warning government about energy costs

52

52

Pharmacy Times

AUGUST 19, 2022

Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.

65

65

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

AUGUST 19, 2022

The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has provided interim policy recommendations for the usage of French company Valneva’s Covid-19 vaccine, VLA2001. According to the recommendations, two 0.5ml intramuscular doses of the vaccine are intended to be given as part of the initial dosing regimen. The second dose should be given a minimum of 28 days following the first shot. .

Vaccines 52

Vaccines Immunization 52

Pharmacy Times

AUGUST 19, 2022

Using specific data and technology can help advance targeted recruitment goals for trials.

65

65

Pharmaceutical Technology

AUGUST 19, 2022

The European Commission (EC) has granted approval for Celltrion Healthcare ’s Vegzelma (CT-P16) to treat metastatic breast cancer, advanced and/or metastatic renal cell cancer, non-small cell lung cancer, ovarian cancer, metastatic carcinoma of the colon or rectum and cervical cancer. Vegzelma (CT-P16) is a bevacizumab biosimilar referencing Genentech’s Avastin, which is approved in the EU.

FDA 52

FDA 52

Pharmacy Times

AUGUST 19, 2022

Resources for health care professionals include FDA’s patient eligibility screening checklist tool for prescribers.

65

65

Pharmaceutical Technology

AUGUST 19, 2022

The UK National Institute for Health and Care Excellence (NICE) has r ecommended Vifor Fresenius Medical Care Renal Pharma’s Tavneos (avacopan) plus rituximab or cyclophosphamide to treat adults with two ANCA-associated vasculitis (AAV) forms. The treatment is indicated for severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the two forms of AAV.

52

52

Pharmacy Times

AUGUST 19, 2022

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.

Immunization 65

Immunization 65

pharmaphorum

AUGUST 19, 2022

The European Commission has approved Oncopeptides’ Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words those who don’t respond to all three of the major classes of treatment for the blood cancer. The approval means that Pepaxti (melphalan flufenamide) can now be used as a rescue therapy for adults with multiple myeloma who have previously failed treatment with at least one proteasome inhibitor, one im

FDA 52

FDA Chemotherapy 52

Pharmacy Times

AUGUST 19, 2022

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

FDA 65

FDA 65

pharmaphorum

AUGUST 19, 2022

Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started a restructuring process and called in investment bank Carnegie to help explore its options. The Norwegian biotech was hit hard in July when the PARADIGME study of Betalutin ( 177 Lu lilotomab satetraxetan) – an anti-CD37 antibody radionuclide conjugate being tested as a third-line therapy for patients with follicular lymphoma – was abandoned after being plagued with recruitment issues.

52

52

Pharmacy Times

AUGUST 19, 2022

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

65

65

pharmaphorum

AUGUST 19, 2022

Australia’s CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial year which ends on 30 June next year. The VANGUARD trial of garadacimab, a Factor XIIa inhibitor, compared a subcutaneous injection of garadacimab given every four weeks to placebo on its ability to prevent the swelling attacks that are a key feature of HAE.

FDA 52

FDA 52

Pharmaceutical Commerce

AUGUST 19, 2022

CDMO filling capacity now exceeds 50 million units yearly.

52

52

pharmaphorum

AUGUST 19, 2022

Who remembers that line from the movie Zoolander, “ the files are IN the computer ?!” Twenty years later and we’re now all painfully familiar with our computer’s file structure. But as we continue to digitise clinical trials, has access to new streams of valuable data become easier because “the data is IN the cloud”? Connected sensor technologies and tools, from wearables, smart speakers, and bed mats to ingestible sensing capsules and implantables, are capturing unprecedented flows of data with

Documentation 52

Documentation Patient Care Hospitals FDA 52

Pharmacy Times

AUGUST 19, 2022

Professionals address key challenges including structural racism and the hematology-oncology pharmacist great migration.

50

50

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. The German pharma acquired rights to the TRPV1 agonist also known as MTX-071 last year when it acquired Swiss biotech Mestex, and has started dosing patients in one of three planned phase 3 trials in osteoarthritis of the knee.

Compounding 52

Compounding 52